PDB-code
Browse PDE entries (page 23 of 31)
First 19 20 21 PreviousLast27 26 25 Next| # | Species | PDE Type | PDB | Chain | Alternate Model | Ligand | Details | File |
|---|---|---|---|---|---|---|---|---|
 | Human | PDE4D | 3g4i | D | 1-(3-nitrophenyl)-3-(pyridin-4-ylmethyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione |  | ||
| Human | PDE4D | 3g4k | A | A | ROLIPRAM | | |
| Human | PDE4D | 3g4k | A | B | ROLIPRAM | | |
| Human | PDE4D | 3g4k | B | A | ROLIPRAM | | |
| Human | PDE4D | 3g4k | B | B | ROLIPRAM | | |
| Human | PDE4D | 3g4k | C | A | ROLIPRAM | | |
| Human | PDE4D | 3g4k | C | B | ROLIPRAM | | |
| Human | PDE4D | 3g4k | D | A | ROLIPRAM | | |
| Human | PDE4D | 3g4k | D | B | ROLIPRAM | | |
| Human | PDE4D | 3g4l | A | 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE | | ||
| Human | PDE4D | 3g4l | B | 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE | | ||
| Human | PDE4D | 3g4l | C | 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE | | ||
| Human | PDE4D | 3g4l | D | 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE | | ||
| Human | PDE4D | 3g58 | A | 8-(3-nitrophenyl)-6-(pyridin-4-ylmethyl)quinoline | | ||
| Human | PDE4D | 3g58 | B | 8-(3-nitrophenyl)-6-(pyridin-4-ylmethyl)quinoline | | ||
| Human | PDE4D | 3g58 | C | 8-(3-nitrophenyl)-6-(pyridin-4-ylmethyl)quinoline | | ||
| Human | PDE4D | 3g58 | D | 8-(3-nitrophenyl)-6-(pyridin-4-ylmethyl)quinoline | | ||
| Human | PDE4D | 3iad | A | A | 1-{4-[(2-fluoro-6-methoxy-3'-nitrobiphenyl-3-yl)methyl]phenyl}urea | | |
| Human | PDE4D | 3iad | A | B | 1-{4-[(2-fluoro-6-methoxy-3'-nitrobiphenyl-3-yl)methyl]phenyl}urea | | |
| Human | PDE4D | 3iad | B | A | 1-{4-[(2-fluoro-6-methoxy-3'-nitrobiphenyl-3-yl)methyl]phenyl}urea | | |
| Human | PDE4D | 3iad | B | B | 1-{4-[(2-fluoro-6-methoxy-3'-nitrobiphenyl-3-yl)methyl]phenyl}urea | | |
| Human | PDE4D | 3iad | C | A | 1-{4-[(2-fluoro-6-methoxy-3'-nitrobiphenyl-3-yl)methyl]phenyl}urea | | |
| Human | PDE4D | 3iad | C | B | 1-{4-[(2-fluoro-6-methoxy-3'-nitrobiphenyl-3-yl)methyl]phenyl}urea | | |
| Human | PDE4D | 3iad | D | A | 1-{4-[(2-fluoro-6-methoxy-3'-nitrobiphenyl-3-yl)methyl]phenyl}urea | | |
| Human | PDE4D | 3iad | D | B | 1-{4-[(2-fluoro-6-methoxy-3'-nitrobiphenyl-3-yl)methyl]phenyl}urea | | |
| Human | PDE4D | 3iak | A | A | 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXYISOQUINOLINE | | |
| Human | PDE4D | 3iak | A | B | 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXYISOQUINOLINE | | |
| Human | PDE4D | 3k4s | A | A | (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one | | |
| Human | PDE4D | 3k4s | A | B | (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one | | |
| Human | PDE4D | 3sl3 | A | A | |
This research was performed as part of the "Phosphodiesterase inhibitors for neglected parasitic diseases" (PDE4NPD) programme, which is supported by the European Union 7th Framework Program (FP7/2007-2013) under grant agreement n° 602666.
